<scp>SHP2</scp> inhibition displays efficacy as a monotherapy and in combination with <scp>JAK2</scp> inhibition in preclinical models of myeloproliferative neoplasms

Garima Pandey(Moffitt Cancer Center), Gary W. Reuther(Moffitt Cancer Center)
American Journal of Hematology
March 5, 2024
10.1002/ajh.27282
Cited by 4

Related Papers

ALK-Activating Homologous Mutations in LTK Induce Cellular Transformation
|PLoS ONE|2012|39
The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells
|Oncotarget|2015|38
Activation of JAK2-V617F by Components of Heterodimeric Cytokine Receptors
|Journal of Biological Chemistry|2010|30